Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)
Status:
Recruiting
Trial end date:
2023-07-11
Target enrollment:
Participant gender:
Summary
This study investigates 3 different doses of orismilast modified release compared to placebo
in adult patients with moderate-to-severe atopic dermatitis. The purpose of the study is to
assess the effect of orismilast modified release in moderate-to-severe atopic dermatitis and
assess the safety aspects of these 3 different doses. The patients will receive an oral
treatment of either orismilast modified release tablets or placebo tablets 2 times a day for
16 weeks.